GlassScriptPhysician profile
Kevin Andrew Jones
NPI 1215467055
$12,751.62
in general payments reported to CMS, 2019-2025
38 companies · $3,288 in 2025
The $3,288 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $120 · 2022: $1,996 · 2023: $3,441 · 2024: $3,398 · 2025: $3,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,077.62 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,936.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,160.09 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,114.24 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,105.56 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,058.19 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,006.99 | 2019-2025 | |
| Corium, LLC | $679.60 | 2022-2025 | Azstarys, Azstarys |
| Janssen Pharmaceuticals, INC | $415.48 | 2020-2025 | Spravato, Xarelto |
| Otsuka America Pharmaceutical, INC. | $375.93 | 2023-2025 | Rexulti |
| Lundbeck LLC | $352.34 | 2022-2025 | Rexulti, Vyepti |
| Axsome Therapeutics, INC. | $349.64 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $322.72 | 2022-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.06 | 2022-2025 | Jardiance, Spiriva Respimat, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.18 | 2022-2025 | Xifaxan, Relistor, Trulance |
| Abbott Laboratories | $263.26 | 2022-2025 | Freestyle Libre 3 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $235.76 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $228.20 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $210.10 | 2022-2025 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $198.86 | 2019-2024 | Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $194.49 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $136.24 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $111.92 | 2022-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $90.06 | 2024-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $81.59 | 2022 | |
| Currax Pharmaceuticals LLC | $79.72 | 2023 | Nexletol, Onzetra Xsail, Contrave |
| Gilead Sciences, INC. | $79.63 | 2019 | |
| Ironwood Pharmaceuticals, INC | $76.99 | 2022-2024 | Linzess |
| Novartis Pharmaceuticals Corporation | $72.09 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $43.84 | 2023 | |
| Viatris Specialty LLC | $40.29 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $23.91 | 2023 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $22.54 | 2023 | Inspire |
| Medtronic, INC. | $20.88 | 2023 | Intellis Adaptivestim |
| Boston Scientific Corporation | $19.70 | 2024 | Ams 700 |
| Azurity Pharmaceuticals, INC. | $18.85 | 2023 | Horizant |
| Irhythm Technologies, INC. | $17.17 | 2024 | Zio Xt Patch, Zio Monitor |
| Phathom Pharmaceuticals, INC. | $16.80 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $14.55 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.